Valvular heart failure: evolving pharmacological approaches

Kieran F Docherty; Catherine M Otto; John J V McMurray

doi:10.1093/eurheartj/ehaf1079

Valvular heart failure: evolving pharmacological approaches

Eur Heart J. 2026 Jan 13:ehaf1079. doi: 10.1093/eurheartj/ehaf1079. Online ahead of print.

Authors

Kieran F Docherty¹, Catherine M Otto², John J V McMurray¹

Affiliations

¹ BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland G12 8TA, UK.
² Division of Cardiology, University of Washington School of Medicine, Seattle, WA, USA.

PMID: 41528050
DOI: 10.1093/eurheartj/ehaf1079

Abstract

Valve disease and heart failure are intricately linked in a bidirectional relationship. Heart failure is both a frequent cause and a common consequence of valvular heart disease. This review will provide an overview of the evidence for medical therapy to prevent valve disease progression and to prevent or treat established heart failure in patients with primary and secondary valve disease.

Keywords: Heart failure; Valvular heart disease.

© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.